Nigel B. Jamieson
Glasgow Royal Infirmary
CancerPancreatic cancerAdenocarcinomaGeneral surgeryMedicine
What is this?
Publications 137
#1Alma Moekotte (UvA: University of Amsterdam)H-Index: 2
#2Giuseppe MalleoH-Index: 29
Last. Louisa BolmH-Index: 5
view all 32 authors...
BACKGROUND: Whether patients who undergo resection of ampullary adenocarcinoma have a survival benefit from adjuvant chemotherapy is currently unknown. The aim of this study was to compare survival between patients with and without adjuvant chemotherapy after resection of ampullary adenocarcinoma in a propensity score-matched analysis. METHODS: An international multicentre cohort study was conducted, including patients who underwent pancreatoduodenectomy for ampullary adenocarcinoma between 2006...
#1Antonio Pea (Glas.: University of Glasgow)
#1Antonio Pea (Glas.: University of Glasgow)H-Index: 12
Last. Chiara Braconi (Glas.: University of Glasgow)H-Index: 23
view all 3 authors...
The majority of the human genome comprises of DNA genes that are translated into RNAs but not into proteins. These RNA molecules are named non-coding RNAs (ncRNA). While in the past it was thought that ncRNAs would be redundant without relevant functions, it is now well established that ncRNAs identify a class of regulatory molecules that finely tune cell homeostasis and are deregulated in disease states, including Hepatocellular Carcinoma (HCC). Of note, the number of ncRNAs within a cell incre...
1 CitationsSource
#1Malinda ItchinsH-Index: 2
#2Terence C. Chua (Griffith University)H-Index: 1
Last. Andrew KneeboneH-Index: 24
view all 15 authors...
OBJECTIVES: Little data exist on the utility of fluorodeoxyglucose positron emission tomography (FDG-PET) in operable pancreatic ductal adenocarcinoma (PDAC) treated with neoadjuvant (NA) therapy. METHODS: Consecutively treated patients with potentially operable PDAC were recruited from a quaternary referral center between 2015 and 2018. Data were collated on demographic, clinical, radiological, treatment, and disease-free and overall survival (OS) outcome measures, correlated with FDG-PET findi...
#1Stephan DreyerH-Index: 4
#2Nigel B. JamiesonH-Index: 33
Last. David K. ChangH-Index: 31
view all 6 authors...
1 CitationsSource
#1Stephan DreyerH-Index: 4
#2Nigel B. JamiesonH-Index: 33
Last. David K. ChangH-Index: 31
view all 7 authors...
1 CitationsSource
Observation or resection of pancreatic intraductal papillary mucinous neoplasm: An ongoing tug of war
#1Angela ChouH-Index: 24
#2Ian BrownH-Index: 13
Last. Anthony J. GillH-Index: 50
view all 16 authors...
Pancreatic acinar cell carcinoma is relatively rare (1 to 2% of pancreatic malignancies) but may be under-recognized. In contrast to pancreatic ductal adenocarcinoma, most acinar cell carcinomas lack mutations in KRAS, DPC, CDKN2A or TP53, but appear to have a high incidence of gene rearrangements, with up to 20% reported to be driven by BRAF fusions. With the development of a new class of RET-specific tyrosine kinase inhibitors, which appear to have particularly strong activity against RET gene...
#2Ammar A. JavedH-Index: 12
Last. Claudio BassiH-Index: 80
view all 25 authors...
1 CitationsSource
#1Holly Brunton (Glas.: University of Glasgow)
Last. Andrew V. BiankinH-Index: 1
view all 44 authors...
The identification of molecularly defined subgroups of Pancreatic ductal Adenocarcinoma (PDAC) has the potential to transform clinical practice. There is now a growing consensus that PDAC can be divided into transcriptomic subtypes with 2 broad linages referred to as Classical (Pancreatic) and Squamous. We find that these two subtypes are driven by distinct metabolic phenotypes. Loss of genes that drive endodermal linage specification, HNF4A and GATA6, switch metabolic profiles from Classical (P...
Background: FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients. The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated. Methods: We performed a systematic review and patient-level meta-analysis on neoadjuvant FOLFIRINOX in patients with BRPC. Studies with BRPC patients who received FOLFIRINOX as first-line neoadjuvant treatment were included. Primary endpoint was overall survival (OS). Secondary endpoi...
3 CitationsSource